38 results about "Eye posterior segment" patented technology

The invention provides a liposome for delivery to the posterior segment of the eye, comprising (A) a phospholipid, (B) a charged substance, and / or (C) a membrane-reinforcing substance; the liposome having a rigidity that provides the liposome with cell membrane permeability, and having a mean particle diameter of 1 μm or less; and a pharmaceutical composition for a disease in the posterior segment of an eye, comprising a drug encapsulated in the liposome. The liposome is delivered to the posterior segment of the eye by instillation, and is non-cytotoxic; and the pharmaceutical composition for a disease in the posterior segment of the eye comprises the liposome.

The present invention provides a drug delivery system by noninvasive administration, which is excellent in drug transfer to a tissue of the posterior segment of the eye via a local eye tissue. By administering a solid composition comprising a drug and a mucoadhesive substance having an adhesion strength of from 200 to 1000 g in the conjunctival sac, a drug delivery system excellent in drug transfer to a tissue of the posterior segment of the eye via a local eye tissue can be constructed.

Provided are pharmaceutical carriers based on oil-in-water microemulsions and methods of making same. Also provided are pharmaceutical compositions comprising a carrier of the invention and a lipophilic active pharmaceutical ingredient (API), as well as methods for making same. The pharmaceutical compositions are particularly suitable for use in formulating lipophilic APIs for topical administration to the eye. Specifically included are pharmaceutical compositions comprising fenofibrate or fenofibric acid as API. Also provided is a method of treating a disease of the posterior segment of the eye. Also provided is a pharmaceutical composition comprising a compound represented byformulated for topical administration to the eye.

The present invention relates to topical formulations comprising a compound of the following formula:for treating ocular neovascularization. The Compound-I is present in a solution or a suspension in about 0.005% to about 5.0% w / v, such that the solution or suspension delivers the compound at the posterior segment of the eye for inhibiting VEGF in the retina and / or the choroid.

A topical ophthalmic formulation of peptides and their use for the treatment and / or local prevention of ocular diseases, preferably posterior segment eye diseases.

The present invention relates to an ophthalmic formulation comprising citicoline and liposomes to be used in treating glaucoma. The inventors have found that the liposomes result to be particularly effective in carrying citicoline in the posterior segment of the eye (vitreous chamber) and in reaching the retina and the optic nerve head.

The present invention concerns nanoparticles useful for treating posterior segment ocular diseases or conditions, such as macular degeneration and diabetic retinopathy; compositions comprising the nanoparticles; methods for producing the nanoparticles; and methods for treating posterior segment ocular diseases or conditions, comprising administering the nanoparticles or compositions to the ocular posterior segment of an afflicted eye.

It is intended to provide a continuous drug delivery system targeting a tissue in the posterior segment of eye which needs no frequent administration and shows little tissue invasion. Namely, a drug delivery system whereby a drug is selectively transferred into the posterior segment of eye, thereby lessening effects of the drug transfer on the anterior segment of eye. By administering fine grains containing a drug under Tenon's capsule, a drug delivery system ensuring the selective transfer of the drug toward the posterior segment of eye and maintenance of an efficacious drug concentration can be constructed.

The invention discloses an implantable intraocular quantitative medicine injection pump which comprises a medicine guiding pipe and a medicine adding bag, wherein a medicine inlet and a medicine outlet are arranged on the medicine adding bag, and one end of the medicine guiding pipe is communicated with the medicine outlet. While in use, the medicine adding bag is filled with medicine liquid and is punctured at the cornea segment, the medicine guiding pipe is inserted, the medicine adding bag is extruded, and the medicine liquid flows into the vitreous body through the medicine guiding pipe. The capacity of the medicine adding bag can be designed into a quantity required for single medication, an operator does not require repeating measuring medicine quantity during each medication, and the working efficiency is increased. The device can quantitatively medicate the eye posterior segment for multiple times without intraocular operation, is safe for implantation and easy for taking out,can reduce intraocular infection risk, can realize long-term sustainable medication to form effective medicine concentration and can enhance the local curative effects of the medicine in the eyes. The purpose of treating a series of intractable eye diseases requiring overall or local frequent medication is achieved, and the invention has great economical and social benefits and is very applicableto clinic application.

The invention relates to a new therapeutic approach for the treatment and / or prevention of a disease of the posterior segment of the eye, in particular for retinal and optic nerve pathologies. Dobesilic acid and / or a pharmaceutically acceptable salt, or an ester of any of the acid or the salt, are proposed for use topically administered onto eye surface. There are also disclosed new compositions comprising dobesilic acid and / or a pharmaceutically acceptable salt, or an ester of any of the acid or the salt, adapted for performing the treatment and / or prevention of diseases of the posterior segment of the eye.